We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Gastroenterology

Gastroenterology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Universal ESD for Large Barrett’s Cancers: Shifting the Paradigm Toward Curative R0 Resection
GastroenterologyBarrett's esophagusEMR vs ESD

Universal ESD for Large Barrett’s Cancers: Shifting the Paradigm Toward Curative R0 Resection

By MedXY|Mar 10, 2026

A multicenter study demonstrates that prioritizing endoscopic submucosal dissection (ESD) for Barrett’s cancers >15mm significantly improves R0 resection rates and survival, particularly in T1b disease, compared to traditional endoscopic

Artificial Intelligence in Gastric Endoscopy: Decoding the Findings of a Landmark Multicenter Randomized Controlled Trial
Clinical Updatesartificial intelligenceclinical trial

Artificial Intelligence in Gastric Endoscopy: Decoding the Findings of a Landmark Multicenter Randomized Controlled Trial

By MedXY|Mar 11, 2026

A large-scale multicenter RCT investigating AI-assisted gastric neoplasm detection found no significant improvement in pathologically confirmed detection rates but demonstrated significant reductions in procedural blind spots and benefits f

Uncovering the Hepatocyte CEBPA-ORM1 Axis: A Novel Regulatory Pathway and Biomarker in Alcohol-Associated Liver Disease
Clinical Updatesalcohol-associated liver diseaseClinical Updates

Uncovering the Hepatocyte CEBPA-ORM1 Axis: A Novel Regulatory Pathway and Biomarker in Alcohol-Associated Liver Disease

By MedXY|Mar 10, 2026

This review synthesizes recent findings identifying the CEBPA-ORM1 axis as a critical suppressor of alcohol-associated liver disease, highlighting its potential as both a therapeutic target and a diagnostic biomarker for disease staging.

Beyond Clinical Remission: Why Diet and Gut Signatures Remain Perturbed in Crohn’s Disease
GastroenterologyClinical RemissionCrohn’s disease

Beyond Clinical Remission: Why Diet and Gut Signatures Remain Perturbed in Crohn’s Disease

By MedXY|Mar 10, 2026

A multi-omic study reveals that despite effective immune suppression, Crohn’s disease patients in remission exhibit persistent dietary, microbial, and metabolic abnormalities. This research highlights the critical role of ultraprocess

Global Diversity in Autoimmune Gastritis: Deciphering Regional Phenotypes and Neoplastic Risks
GastroenterologyGastric Cancerneuroendocrine tumors

Global Diversity in Autoimmune Gastritis: Deciphering Regional Phenotypes and Neoplastic Risks

By MedXY|Mar 9, 2026

An international multicentre study of 1,240 patients reveals that autoimmune gastritis presentation varies by region, with distinct risk factors—including age, intestinal metaplasia, and extreme hypergastrinemia—driving the development of g

New Consensus on APC Mosaicism: Transforming the Diagnosis and Management of Unexplained Polyposis
Gastroenterologycolorectal cancergastroenterology

New Consensus on APC Mosaicism: Transforming the Diagnosis and Management of Unexplained Polyposis

By MedXY|Mar 9, 2026

A landmark study in Gastroenterology reveals that APC mosaicism accounts for nearly 10% of unexplained colorectal polyposis. New guidelines recommend specific testing thresholds and surveillance strategies to prevent colorectal cancer in th

Unmasking DARS1: A Dual-Action Driver of Hepatocellular Carcinoma Aggressiveness via SAGA-MYC Signaling
Gastroenterologyhepatocellular carcinomaliquid biopsy

Unmasking DARS1: A Dual-Action Driver of Hepatocellular Carcinoma Aggressiveness via SAGA-MYC Signaling

By MedXY|Mar 8, 2026

Researchers have identified DARS1 as a critical oncogenic driver in hepatocellular carcinoma. Beyond its role in protein synthesis, DARS1 enters the nucleus to modulate MYC signaling through the SAGA complex, offering a new therapeutic vuln

The Tryptophan Tug-of-War: How Faecalibacterium prausnitzii Counteracts Bacteroides fragilis in Colorectal Cancer
Gastroenterologycolorectal cancergut microbiome

The Tryptophan Tug-of-War: How Faecalibacterium prausnitzii Counteracts Bacteroides fragilis in Colorectal Cancer

By MedXY|Mar 8, 2026

A comprehensive multi-omics study reveals that Faecalibacterium prausnitzii metabolizes tryptophan into picolinic acid, which antagonizes the pro-tumorigenic effects of enterotoxigenic Bacteroides fragilis by down-regulating TCERG1 and CKAP

Adjuvant Imatinib Significantly Extends Survival and Delays Recurrence in KIT Exon 9-Mutant GIST: Evidence from a Global Multicenter Cohort
Gastroenterologyprecision oncology

Adjuvant Imatinib Significantly Extends Survival and Delays Recurrence in KIT Exon 9-Mutant GIST: Evidence from a Global Multicenter Cohort

By MedXY|Mar 7, 2026

This international multicenter study demonstrates that adjuvant imatinib therapy significantly improves both recurrence-free and overall survival in patients with resected KIT exon 9-mutant GIST, providing clarity on optimal management for

More is Not Always Better: The GOULASH Trial Challenges High-Energy Early Nutrition in Acute Pancreatitis
GastroenterologyClinical Nutritionenteral feeding

More is Not Always Better: The GOULASH Trial Challenges High-Energy Early Nutrition in Acute Pancreatitis

By MedXY|Mar 6, 2026

The multicentre GOULASH trial reveals that high-energy nutrition in the early phase of acute pancreatitis does not improve outcomes and may increase risks of organ failure and pain relapse compared to a gradual caloric increase, leading to

Stem Cell Therapy for Complex Perianal Fistulas: Why the ADMIRE CD II Trial Missed Its Mark
GastroenterologyCrohn’s diseasestem cell therapy

Stem Cell Therapy for Complex Perianal Fistulas: Why the ADMIRE CD II Trial Missed Its Mark

By MedXY|Mar 6, 2026

The ADMIRE CD II Phase 3 trial failed to show a significant benefit of darvadstrocel over placebo for complex perianal fistulas in Crohn’s disease, primarily due to an unexpectedly high remission rate in the placebo-controlled surgica

Precision Dosing Without Compromise: UGT1A1 Genotype-Guided Irinotecan Dosing Maintains Survival in Gastrointestinal Cancers
GastroenterologyIrinotecanoncology

Precision Dosing Without Compromise: UGT1A1 Genotype-Guided Irinotecan Dosing Maintains Survival in Gastrointestinal Cancers

By MedXY|Mar 4, 2026

A multicentre cohort study confirms that upfront 30% irinotecan dose reductions for UGT1A1 poor metabolisers effectively prevent severe toxicity without compromising progression-free or overall survival in colorectal and pancreatic cancer p

Digital Health Literacy and Proctology: Critically Evaluating Hemorrhoid Information Quality on Chinese TikTok (Douyin)
Clinical Updatesdigital healthTikTok

Digital Health Literacy and Proctology: Critically Evaluating Hemorrhoid Information Quality on Chinese TikTok (Douyin)

By MedXY|Mar 2, 2026

This cross-sectional study evaluates the quality and reliability of hemorrhoid-related content on Chinese TikTok, revealing that while physician-led content is high-quality, lower-quality videos often receive higher user engagement.

Potent Viral Suppression and Safety of ALG-000184: Insights from a Phase 1 Trial in Chronic HBV Infection
GastroenterologyALG-000184Capsid Assembly Modulator

Potent Viral Suppression and Safety of ALG-000184: Insights from a Phase 1 Trial in Chronic HBV Infection

By MedXY|Mar 2, 2026

This Phase 1 trial demonstrates that ALG-000184, a novel Class-E capsid assembly modulator, significantly reduces HBV DNA and RNA levels in patients with chronic hepatitis B, maintaining a favorable safety profile and supporting its potenti

Potent Antiviral Activity of the Class-E Capsid Assembly Modulator ALG-000184 in Chronic Hepatitis B: Insights from a Phase 1 Randomized Trial
Clinical UpdatesALG-000184Capsid Assembly Modulator

Potent Antiviral Activity of the Class-E Capsid Assembly Modulator ALG-000184 in Chronic Hepatitis B: Insights from a Phase 1 Randomized Trial

By MedXY|Mar 2, 2026

This review synthesizes the Phase 1 trial findings of ALG-000184, a novel capsid assembly modulator, demonstrating significant multi-log reductions in HBV DNA and RNA with a favorable safety profile in chronic HBV patients.

Cyclic Exclusive Enteral Nutrition: A New Paradigm for Drug-Free Remission in Pediatric Crohn’s Disease
GastroenterologyCrohn’s disease肠内营养

Cyclic Exclusive Enteral Nutrition: A New Paradigm for Drug-Free Remission in Pediatric Crohn’s Disease

By MedXY|Mar 2, 2026

The CD-HOPE trial reveals that cyclic exclusive enteral nutrition (C-EEN) is superior to daily partial enteral nutrition (PEN) for maintaining drug-free remission in children with Crohn’s disease, providing a critical alternative to long-te

PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial
Gastroenterologyneoadjuvant therapyPancreatic Cancer

PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial

By MedXY|Mar 2, 2026

The Phase 3 CASSANDRA trial reveals that the four-drug PAXG regimen significantly improves event-free survival compared to mFOLFIRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, potentially redefi

Beyond MELD: The Liver Immune Frailty Index (LIFI) Predicts Post-Transplant Mortality with High Precision
Gastroenterologybiomarkersliver transplantation

Beyond MELD: The Liver Immune Frailty Index (LIFI) Predicts Post-Transplant Mortality with High Precision

By MedXY|Feb 21, 2026

Researchers have developed the Liver Immune Frailty Index (LIFI), a biomarker-based tool using fractalkine and MMP3 to predict post-liver transplant mortality. With a C-statistic of 0.83, LIFI identifies high-risk candidates, potentially tr

Long-Term Parity in Adhesiolysis: 5-Year Results from the LASSO Randomized Trial Challenge Laparoscopic Superiority
Gastroenterologyclinical trialLaparoscopy

Long-Term Parity in Adhesiolysis: 5-Year Results from the LASSO Randomized Trial Challenge Laparoscopic Superiority

By MedXY|Feb 19, 2026

The 5-year follow-up of the LASSO randomized clinical trial demonstrates that while laparoscopic adhesiolysis offers short-term recovery benefits, it provides no significant long-term advantage over open surgery regarding SBO recurrence, in

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort
GastroenterologyHepatologyliver fibrosis

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort

By MedXY|Feb 17, 2026

The Phenome India study identifies a 38.9% age-adjusted prevalence **Constructing the JSON Object** Now, I’m carefully constructing the JSON object, which needs to be a valid, parseable string. I’m focusing on incorporating the

Prev
15 / 25
1…1314151617…25
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Browse by specialty

Open language-specific specialty feeds and department pages.

news6829 articlesCardiology1403 articlesClinical Updates1315 articlesOncology1176 articlesDiabetes & Endocrinology868 articlesNeurology834 articlesPublic Health605 articlesGastroenterology586 articles
Hematology-Oncology
513 articles
Pediatrics493 articles
Internal Medicine464 articles